Advertisement

Topics

Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients

2014-07-23 21:48:49 | BioPortfolio

Summary

In this study, we, the investigators at National Taiwan University Hospital, will evaluate the efficacy of pharmacological therapy targeted to reduce insulin resistance (pioglitazone) on the progression and compositional change of non-obstructive coronary atherosclerotic plaques and coronary calcification by serial intravascular ultrasound (IVUS)/multi-detector-row computed tomography (MDCT) follow-up in patients with type 2 diabetes or non-diabetic metabolic syndrome during a 2-year period.

Description

Background: Type 2 diabetes and its antecedent, metabolic syndrome, are important risk factors for premature and accelerated atherosclerotic cardiovascular diseases. However, glycemic control by provision of endogenous or exogenous insulin induced only modest and not statistically significant reduction of the risk of myocardial infarction. We and other investigators have demonstrated that the use of insulin sensitizer, thiazolidinediones, resulted in favorable antiatherosclerotic effects in patients with type 2 diabetes or non-diabetic metabolic syndrome. It has become increasingly clear that morbidity and mortality associated with coronary artery disease (CAD) are often associated with lesions that are not obstructive but prone to rupture, the so-called vulnerable plaques. Conventional coronary angiography is not suitable for identifying vulnerable plaques. They may be detected by intravascular ultrasound (IVUS) and recently developed high-resolution 16-slice multi-detector computed tomography (MDCT). Nevertheless, whether this modality could be used as a guide for optimizing medical treatment of CAD has never been explored in the medical literature. In this study, we will evaluate the efficacy of pharmacological therapy targeted to reduce insulin resistance on the progression and compositional change of non-obstructive coronary atherosclerotic plaques and coronary calcification by serial IVUS/MDCT follow-up in patients with type 2 diabetes or non-diabetic metabolic syndrome during a 2-year period.

Methods and Expected Results: Patients aged ≥18 years conformed to the diagnosis of type 2 diabetes or metabolic syndrome criteria in ATP III and with objective evidence of myocardial ischemia will undergo EBCT, MDCT coronary angiography, percutaneous coronary angiography and intervention if appropriate, and IVUS study if non-obstructive coronary plaques are identified in the MDCT examination. Patients deemed eligible (with one or more ≥ 20% and < 70% stenosis in at least one coronary artery) will then be randomly assigned in a 1:1 ratio to receive pioglitazone (30 mg/d) or placebo in an open-label fashion. Patients with type 2 diabetes assigned to the placebo group are not allowed to be treated with any insulin sensitizer. The target for glycemic control in patients with type 2 diabetes in both groups is reduction of HbA1c to ≤ 7.0%. A total of 120 patients are planned to be included, and the follow-up period is 2 years. To assess the progression of coronary atherosclerosis, MDCT coronary angiography/scanning will be performed at baseline and 3, 6, 12, and 24 months of follow-up. Follow-up coronary angiography and intravascular ultrasound study will be performed at 6 months if patients agree. Blood samples will also be obtained at baseline and 3, 6, 12, and 24 months of follow-up for the measurement of various conventional and novel coronary risk factors. We also obtain DNA specimen from blood drawn at baseline for genotyping. The primary end-points include changes from baseline in total plaque volume, plaque characteristics (as determined by CT-density values and other morphological features), and total coronary calcium score. The secondary end-points include percent change from baseline in calcium volume score in each coronary artery, percent change from baseline in plasma glucose/insulin homeostatic parameters and various risk markers, and the occurrence of a composite of major cardiovascular events (death from any cause, non-fatal myocardial infarction, stroke, and target vessel revascularization).

Clinical Significance: This is the first human study to assess the antiatherosclerotic effects of insulin sensitizer by directly visualizing the atherosclerotic plaques of the whole coronary trees. It will provide us great insights regarding the evolution of coronary plaques and techniques of measuring the total vulnerability burden of the coronary arteries.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Conditions

Coronary Atherosclerosis

Intervention

pioglitazone

Location

Division of Cardiology, Department of Internal Medicine and Department of Medical Imaging, National Taiwan University Hospital
Taipei
Taiwan
100

Status

Recruiting

Source

National Taiwan University Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:48:49-0400

Clinical Trials [2010 Associated Clinical Trials listed on BioPortfolio]

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis...

Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease

Pioglitazone, a medication of thiazolidinedione group, is capable of triggering the peroxisome proliferator-activated receptors (PPAR-γ). Activation of receptor PPAR-γ regulates carbohyd...

Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes

The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients withou...

Pioglitazone in Impaired Glucose Tolerance

In patients with impaired glucose tolerance (IGT), the researchers want to study the relative effects of pioglitazone, simvastatin, or the combination of both on: - intima media thickn...

Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.

The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on heart functioning before, during and after stent implantation.

PubMed Articles [2354 Associated PubMed Articles listed on BioPortfolio]

Morphometry and hemodynamics of coronary artery aneurysms caused by atherosclerosis.

Atherosclerosis is the first etiology of coronary artery aneurysm (CAA). It is, however, challenging to inhibit the development of CAA. The aim of the study is to carry out morphometric and hemodynami...

Anti-Inflammatory Interleukin-10 is Inversely Related to Coronary Atherosclerosis in People with Hiv.

Interleukin-10 (IL-10) is an anti-inflammatory cytokine that may be protective against coronary atherosclerosis. In an observational study of people with HIV (PWH) and uninfected controls, IL-10 was m...

Identification of novel serum markers for the progression of coronary atherosclerosis in WHHLMI rabbits, an animal model of familial hypercholesterolemia.

The development of serum markers specific for coronary lesions is important to prevent coronary events. However, analyses of serum markers in humans are affected by environmental factors and non-targe...

Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ.

Local macrophage proliferation is linked to enhanced atherosclerosis progression. Our previous study found that troglitazone, a thiazolidinedione (TZD), suppressed oxidized low-density lipoprotein (Ox...

Correlation between coronary atherosclerosis calcification and epicardial adipose tissue volume in patients with nephropathy.

Correlation between coronary atherosclerosis calcification and epicardial adipose tissue (EAT) volume in patients with nephropathy was investigated. A total of 529 patients with high risk of coronary ...

Medical and Biotech [MESH] Definitions

Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.

Complete blockage of blood flow through one of the CORONARY ARTERIES, usually from CORONARY ATHEROSCLEROSIS.

Malformations of CORONARY VESSELS, either arteries or veins. Included are anomalous origins of coronary arteries; ARTERIOVENOUS FISTULA; CORONARY ANEURYSM; MYOCARDIAL BRIDGING; and others.

Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.

Direct myocardial revascularization in which the internal mammary artery is anastomosed to the right coronary artery, circumflex artery, or anterior descending coronary artery. The internal mammary artery is the most frequent choice, especially for a single graft, for coronary artery bypass surgery.

More From BioPortfolio on "Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Radiology
Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...


Searches Linking to this Trial